Relief Therapeutics Holding AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Relief Therapeutics Holding AG
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
InterMune’s therapeutic area for many years has been lung diseases and more specifically idiopathic pulmonary fibrosis (IPF). The company's treatment for IPF, pirfenidone, is the only approved drug, and yet it is not available everywhere. The US FDA, for instance, issued a complete response letter in May. Furthermore, InterMune's original intention of partnering its drug has not been realised. What lies behind such regulatory and commercial reticence?
- Large Molecule
- Other Names / Subsidiaries
- THERAMetrics Holding AG